Pfizer Advances Tilrekimig Into Phase 3 Atopic Dermatitis And Asthma Trials After Phase 2 Study Showed Statistically Significant EASI-75 Gains At Week 16 And No Dose-Dependent Safety Signals
Share
Why It Matters
Pfizer's new skin medicine worked well in early testing. This means the company can now test it on more patients to see if it really helps.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.